Ronald J Ferguson

US Patent:

20190315708, Oct 17, 2019

Filed:

Dec 18, 2017

Appl. No.:

16/471679

Inventors:

Jianming BAO - Shanghai, CN
Ronald FERGUSON - Rahway NJ, US
Xiaolei GAO - Bridgewater NJ, US
Scott HARRISON - West Point PA, US
Sandra L. KNOWLES - Kenilworth NJ, US
Michael Man-chu LO - Kenilworth NJ, US
Jeffrey W. SCHUBERT - West Point PA, US
- Rahway NJ, US
- Shanghai, CN

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 401/04
C07D 401/14
C07D 417/14
C07D 513/04
C07D 405/14
C07D 413/14
C07D 498/08
C07D 491/107

Abstract:

The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

US Patent:

20170275302, Sep 28, 2017

Filed:

Oct 9, 2015

Appl. No.:

15/505266

Inventors:

Alexander PASTERNAK - Kenilworth NJ, US
Barbara PIO - Kenilworth NJ, US
Harry R. CHOBANIAN - Kenilworth NJ, US
Zhi-Cai SHI - Kenilworth NJ, US
Shuzhi DONG - Kenilworth NJ, US
Yan GUO - Kenilworth NJ, US
Shawn P. WALSH - Kenilworth NJ, US
Zhiqiang GUO - Rahway NJ, US
Ronald D. FERGUSON - Rahway NJ, US
Brian CATO - Secaucus NJ, US
- Rahway NJ, US

International Classification:

C07D 519/00
A61K 31/4985
C07D 471/10
A61K 31/435
C07D 498/10
A61K 31/519
A61K 31/437
A61K 31/4365
A61K 31/4375
A61K 31/4355
A61K 45/06
A61K 31/5025

Abstract:

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

US Patent:

20160068532, Mar 10, 2016

Filed:

Apr 25, 2014

Appl. No.:

14/787280

Inventors:

Jongwon LIM - , US
Xianhai HUANG - , US
Ronald D. FERGUSON - Rahway NJ, US
Wei ZHOU - Rahway NJ, US
Christopher W. BOYCE - Rahway NJ, US
Phieng SILIPHAIVANH - Boston MA, US
David J. WITTER - Boston MA, US
Milana M. MALETIC - Rahway NJ, US
Joseph A. KOZLOWSKI - Rahway NJ, US
Kevin J. WILSON - Boston MA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 487/04
C07D 471/14
C07D 471/04

Abstract:

Disclosed are the ERK inhibitors of formula (I) and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I). This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier. This invention also provides a method of inhibiting ERK (i.e., inhibiting the activity of ERK2) in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of formula (I).